

Deficit Reduction Act May Harm Medicaid Patients

BY JOYCE FRIEDEN

Associate Editor, Practice Trends

BALTIMORE — Provisions in the Deficit Reduction Act are likely to profoundly affect health care for Medicaid patients, Cindy Mann said at the annual meeting of the American Society for Law, Medicine, and Ethics.

The Deficit Reduction Act (DRA) of 2005, signed into law last February by President Bush, includes “the most significant statutory changes in the Medicaid program arguably since the late 1980s,” said Ms. Mann, who is a research professor at Georgetown University Health Policy Institute in Washington. “It really is also the first time that Congress has legislated some specific cutbacks aimed at beneficiaries.”

Keeping Health Data Private in Emergency

The Department of Health and Human Services has developed a Web-based decision tool to assist emergency preparedness and help recovery planners use health information while complying with the Health Insurance Portability and Accountability Act of 1996 Privacy Rule.

The tool is aimed at meeting the needs of elderly or disabled persons during and after evacuation. To access the tool, go to www.hhs.gov/ocr/hipaa/decisiontool. ■

INDEX OF ADVERTISERS

Abbott Laboratories	
TriCor	5-6
Forest Pharmaceuticals, Inc.	
Lexapro	22a-22b
Namenda	41-44
GELITA Health Initiative	
Collagen Hydrolysate	54a-54b
Eli Lilly and Company	
Cymbalta	59-60
Merck & Co., Inc.	
Januvia	6a-6b
Zostavax	46a-46d
Novartis Pharmaceuticals Corporation	
Diovan	21-22
Novartis Vaccines	
Corporate	49
Novo Nordisk Inc.	
Novolog 70/30 Mix	27-28
Levemir	45-46
Ortho-McNeil Neurologics	
Topamax	12-14
Pfizer Inc.	
Lyrica	3
Chantix	25-26
Caduet	30-33
Viagra	37-38
Sanofi Aventis	
Apidra	14a-14b
Corporate	52-53
Sanofi Pasteur Inc.	
ADACEL	34a-34b
Sepracor Inc.	
Lunesta	38a-38b
Takeda Pharmaceuticals North America, Inc.	
Corporate	9
Amitiza	17-20
Rozerem	56-58
Wyeth Pharmaceuticals Inc.	
Effexor XR	10a-10d, 50a-50d

Many changes deal with Medicaid coverage requirements for states. The law “gives [states] very broad flexibility to move away from what has been a system of mandatory and optional benefits to a system of benchmark benefits,” said Ms. Mann, who is also executive director of the Center for Children and Families at Georgetown. “One benchmark [states can use] is any state employee plan—not the one most used in your state, or the one that has the highest enrollment of dependents,

it’s any state employee plan that’s offered.”

States could even construct a special plan just to be a benchmark and then offer it to state employees, “and that becomes [the] standard,” she said, at the meeting cosponsored by the University of Maryland.

The other way states can formulate an acceptable plan is by getting the approval of the federal Health and Human Services secretary. The two state plan amendments now approved under the DRA—West Virginia and Kentucky—used the secretary-

approved coverage option, she noted.

DRA also allows states to change benefit packages for some groups and not others, Ms. Mann said. “[States] could have one benchmark package in a rural area of the state and a different one for urban areas. It opens it up to any slice and dice a state decides it wants to do in terms of how it constructs these benchmark packages and to whom they will apply.”

A controversial change imposed by the DRA is a requirement that anyone apply-

FIRST
IN A NOVEL
CLASS OF
SLEEP
AGENTS

Rozerem is indicated for the treatment of insomnia characterized by difficulty with sleep onset. Rozerem can be prescribed for long-term use. Rozerem should not be used in patients with hypersensitivity to any components of the formulation, severe hepatic impairment, or in combination with fluvoxamine. Failure of insomnia to remit after a reasonable period of time should be medically evaluated, as this may be the result of an unrecognized underlying medical disorder. Hypnotics should be administered with caution to patients exhibiting signs and symptoms of depression. Rozerem has not been studied in patients with severe sleep apnea, severe COPD, or in children or adolescents. The effects in these populations are unknown. Avoid taking Rozerem with alcohol. Rozerem has been associated with decreased testosterone levels and increased prolactin levels. Health professionals should be mindful of any unexplained symptoms possibly associated with such changes in these hormone levels. Rozerem should not be taken with or immediately after a high-fat meal. Rozerem should be taken within 30 minutes before going to bed and activities confined to preparing for bed. The most common adverse events seen with Rozerem that had at least a 2% incidence difference from placebo were somnolence, dizziness, and fatigue.

Please see adjacent Brief Summary of Prescribing Information.

ing for Medicaid who says they are a citizen must provide new documentation of their citizenship. "Since 1996 there's been a provision requiring documentation of immigration status, and now there are very strict rules about documentation," she said, adding that federal guidance on how to implement this section of the law is expected shortly.

The law also allows for several demonstration projects. For example, 10 states may start Health Opportunity Accounts, which are "a little like health savings accounts for the Medicaid program," she said. Another measure, championed by Sen. Charles Grassley (R-Iowa), is the Fam-

ily Opportunity Act, which allows families to buy into Medicaid if they have severely disabled children, even if their family income is above the normal cutoff in their state for Medicaid eligibility.

Ms. Mann added that although the law contains profound changes, "it is often overstated what the changes were. In large part, what the DRA didn't do, Congress decided not to do. There was a debate about the areas of benefit guarantees for kids and there was a debate about the cost sharing. So while Congress did go a certain distance, it didn't go further than that certain distance, and I think that's an important consideration." ■

UPCOMING MEETINGS

World Congress of Cardiology

American Academy of Pain Management

European Society for Dermatological Research

Association of Reproductive Health Professionals

Heart Failure Society of America

European Association for the Study of Diabetes

American Society for Bone and Mineral Research

We Are There For You

Start and stay with nonscheduled Rozerem— ZERO evidence of abuse or dependence

Clinical studies show no evidence
of potential abuse, dependence, or withdrawal*

- **First and only**—nonscheduled prescription insomnia medication... not a controlled substance and approved for long-term use¹
- **First and only**—prescription insomnia medication that targets the normal sleep-wake cycle¹
- **First and only**—prescription insomnia medication with no evidence of abuse potential in clinical studies¹
- **First and only**—prescription insomnia medication that does not promote sleep by CNS depression¹
- **Promote sleep with Rozerem**—patients who took Rozerem fell asleep faster than those who took placebo¹
- **One simple 8-mg dose**¹

*Rozerem is not a controlled substance. A clinical abuse liability study showed no differences indicative of abuse potential between Rozerem and placebo at doses up to 20 times the recommended dose (N=14). Three 35-day insomnia studies showed no evidence of rebound insomnia or withdrawal symptoms with Rozerem compared to placebo (N=2082).^{1,2}

Please visit www.rozerem.com

 **Rozerem**TM
ramelteon 8-mg tablets

*Proven for sleep.
Nonscheduled for added safety.*